Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

(2015) Silvio E Inzucchi et al.   Diabetes & Vascular Disease Research

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

(2015) Ian J. Neeland et al.   Diabetes Therapy

Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study

(2015) Ian J. Neeland et al.   Diabetes Therapy

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Index of central obesity as a parameter to replace waist circumference for the definition of metabolic syndrome in predicting cardiovascular disease

(2014) Wenshu Luo et al.   Journal of Cardiovascular Medicine

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial

(2013) H.-U. Haring et al.   DIABETES CARE

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

(2013) C. S. Kovacs et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin

(2013) J. Bolinder et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Adiposopathy, Diabetes Mellitus, and Primary Prevention of Atherosclerotic Coronary Artery Disease: Treating “Sick Fat” Through Improving Fat Function with Antidiabetes Therapies

(2012) Harold E. Bays   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Bariatric Surgery on Cardiac Ectopic Fat

(2012) Bénédicte Gaborit et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes

(2012) Philip R. Schauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: Findings from the National Health and Nutrition Examination Survey 1999-2008*

(2011) Earl S. FORD   Journal of Diabetes

Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk

(2010) M. C. Amato et al.   DIABETES CARE

Index of Central Obesity Is Better Than Waist Circumference in Defining Metabolic Syndrome

(2009) Rakesh M. Parikh et al.   Metabolic Syndrome and Related Disorders

Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk

(2008) Jean-Pierre Després et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review

(2008) T B Chaston et al.   INTERNATIONAL JOURNAL OF OBESITY